Shares of Evolent Health (EVH) surged 10.33% in trading on Thursday, following the company's announcement of better-than-expected third-quarter results and a series of positive developments that paint a bright future for the healthcare solutions provider.

Evolent reported Q3 revenue of $479.53 million, surpassing analyst expectations of $467.50 million. The company also announced over $500 million in new annualized revenue for 2026, stemming from two new revenue agreements. These contracts contribute to a total of thirteen new agreements signed this year, significantly bolstering Evolent's growth prospects.

Adding to the optimism, Evolent provided a strong outlook for both the near and long term. The company expects Q4 2025 revenue between $462 million and $472 million, with full-year 2025 revenue projected to reach $1.87 billion to $1.88 billion. Most notably, Evolent forecasts preliminary 2026 revenue to hit an impressive $2.5 billion, signaling robust growth potential that has excited investors. Furthermore, a newly announced partnership with American Oncology Network aimed at eliminating prior authorization in cancer care demonstrates Evolent's commitment to innovative healthcare solutions, potentially opening up new revenue streams.